These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1289095)

  • 1. Anticardiolipin antibodies and coronary heart disease.
    Tsakiris DA; Marbet GA; Burkart F; Duckert F
    Eur Heart J; 1992 Dec; 13(12):1645-8. PubMed ID: 1289095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course?
    Niessner A; Hornykewycz S; Graf S; Nikfardjam M; Speidl WS; Probst P; Zorn G; Maurer G; Wojta J; Huber K
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):311-6. PubMed ID: 15166916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome.
    Gürlek A; Ozdöl C; Pamir G; Dinçer I; Tutkak H; Oral D
    Int Heart J; 2005 Jul; 46(4):631-8. PubMed ID: 16157954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Connections between ischemic heart disease and anti-cardiolipin antibody positivity].
    Ferlazzo B; Bonanno D; Quattrocchi P; Paino AM; Arrigo F
    Minerva Cardioangiol; 1993 Apr; 41(4):113-7. PubMed ID: 8332265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring of cardiolipin antibodies and plasma lipids in different stages of coronary disease.
    Rebić R; Nastić-Mirić D; Pavlović S; Pokrajcić Z; Bosnjaković V
    Med Pregl; 1993; 46 Suppl 1():20-2. PubMed ID: 8569595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lipoprotein(a) and hemostasis activation markers in angina pectoris].
    Tsakiris DA; Riesen WF; Marbet GA
    Dtsch Med Wochenschr; 1995 Aug; 120(33):1109-13. PubMed ID: 7656834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Location of recurrent cardiovascular events and anticardiolipin antibodies.
    Galán-González J; Rico-Martín S; Calderón-García JF; Antón J; Ramírez-Moreno JM; Álvarez-Rodríguez LR; Sánchez Muñoz-Torrero JF;
    Eur J Clin Invest; 2021 Jul; 51(7):e13533. PubMed ID: 33666941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticardiolipin antibodies, recurrent stroke and vascular events: a prospective study on 210 patients.
    Tănăsescu R; Ticmeanu M; Nicolau A; Uscătescu V; Cojocaru M; Grecu V; Serbănescu A
    Rom J Intern Med; 2005; 43(1-2):79-88. PubMed ID: 16739868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon.
    Rodriguez VE; Gonzalez-Pares EN; Rivera C
    P R Health Sci J; 2006 Dec; 25(4):307-13. PubMed ID: 17550096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticardiolipin antibodies and early infarct of the myocardium].
    Gaeta G; Lupoli S; Brancaccio V; Effuso L; Russo V; Boccalatte A
    Cardiologia; 1998 Jul; 43(7):731-5. PubMed ID: 9738331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticardiolipin and antiphospholipid antibodies in Iraqi patients with angina pectoris.
    Mohammed SN; Mousawy KM; AL Bayati AK; Shawki HB; Ghanim N
    Iran J Immunol; 2008 Mar; 5(1):68-9. PubMed ID: 18319528
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function.
    Palazzuoli A; Deckers J; Calabrò A; Campagna MS; Nuti R; Pastorelli M; Pasqui AL; Bruni F; Auteri A; Puccetti L
    Am J Cardiol; 2006 Nov; 98(10):1322-8. PubMed ID: 17134622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiolipin antibodies in patients with myocardial infarction and unstable angina pectoris].
    Nasonov EL; Noeva EA; Kovalev VIu; Dragnev AG; Lopaeva OV; Ruda MIa
    Kardiologiia; 1992 May; 32(5):32-4. PubMed ID: 1405256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
    Thompson SG; Kienast J; Pyke SD; Haverkate F; van de Loo JC
    N Engl J Med; 1995 Mar; 332(10):635-41. PubMed ID: 7845427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological characteristics of patients with acute coronary syndrome (unstable angina and myocardial infarction)].
    Logacheva IV; Leshchinskiĭ LA; Zvorygin IA
    Klin Med (Mosk); 1999; 77(4):23-5. PubMed ID: 10356912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion molecules and C-reactive protein are associated to adverse events in angina pectoris.
    Eschen O; Christensen JH; Johnsen SP; Dethlefsen C; Schmidt EB
    Scand Cardiovasc J; 2010 Jun; 44(3):153-60. PubMed ID: 20184510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of a prothrombotic state in restenotic patients?
    Brack MJ; More RS; Pringle S; Gershlick AH
    Coron Artery Dis; 1994 Jun; 5(6):501-6. PubMed ID: 7952409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticardiolipin antibodies in ischaemic heart disease: marker or myth?
    Phadke KV; Phillips RA; Clarke DT; Jones M; Naish P; Carson P
    Br Heart J; 1993 May; 69(5):391-4. PubMed ID: 8518060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are the anticardiolipin antibodies a risk factor for coronary artery disease in chronic renal failure patients?
    Ucar E; Kuvandik G; Sert M; Kuvandik C; Temizkan A; Borazan A
    Ren Fail; 2008; 30(8):791-5. PubMed ID: 18791953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.